Sugi Predict

Sugi Predict / Compounds / SCHEMBL18346309

SCHEMBL18346309

SCHEMBL18346309

CC(C)(C)N(C(=O)O)c1cccc(Nc2nc(-c3cnc4c(ccn4S(=O)(=O)c4ccccc4)c3)c3occc3n2)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 5/20 0.34
▸ KDR P35968 3/20 0.33
▸ CDK1 P06493 3/20 0.33
▸ EGFR P00533 3/20 0.33
▸ ERBB4 Q15303 3/20 0.33
▸ AURKA O14965 2/20 0.33
▸ DCLK1 O15075 2/20 0.33
▸ PDPK1 O15530 2/20 0.33
▸ JAK2 O60674 2/20 0.33
▸ ROCK2 O75116 2/20 0.33
▸ PRKD3 O94806 2/20 0.33
▸ MAP4K4 O95819 2/20 0.33
▸ NTRK1 P04629 2/20 0.33
▸ PRKCG P05129 2/20 0.33
▸ LCK P06239 2/20 0.33
▸ FYN P06241 2/20 0.33
▸ LYN P07948 2/20 0.33
▸ RET P07949 2/20 0.33
▸ IGF1R P08069 2/20 0.33
▸ ROS1 P08922 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20211515 0.86 SYK (0.39) FGFR4KDRCDK1EGFRERBB4
SCHEMBL20225398 0.85 MAPT (0.41) FGFR4KDRCDK1EGFRERBB4
SCHEMBL20211544 0.84 CDK1 (0.39) FGFR4KDRCDK1EGFRERBB4
SCHEMBL18346310 0.82 HTR6 (0.33) FGFR4CYP2C19PIK3C3DRD2HTR6
SCHEMBL18346246 0.82 ABL1 (0.43) KDRCDK1EGFRERBB4AURKA
SCHEMBL18346368 0.80 MEN1 (0.40) KDRROCK2PRKD3PRKCGRET
SCHEMBL18346307 0.79 CDK7 (0.43) KDREGFRSRCJAK3ITK
SCHEMBL18345868 0.78 IRAK4 (0.38) FGFR4EGFRERBB4JAK2JAK3
SCHEMBL18345885 0.76 EGFR (0.39) FGFR4KDREGFRJAK3
SCHEMBL19894427 0.76 CYP2C19 (0.49) FGFR4CYP2C19DRD2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10342798-B2 Fused bicyclic pyrimidine derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-07-09 — — US disclosed
US-20180369243-A9 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-12-27 — — US disclosed
US-20180153894-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-07 — — US disclosed
EP-3313529-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF Dana Farber Cancer Institute, Inc. (US) 2018-05-02 — — EP disclosed
WO-2016210291-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180369243-A9 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF CDK3, CDK14, CDK1 FGFR4 258/4885KDR 357/4885CDK1 3/4885
US-10342798-B2 Fused bicyclic pyrimidine derivatives and uses thereof CDK3, CDK14, CDK1 FGFR4 258/4885KDR 357/4885CDK1 3/4885
US-20180153894-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF CDK3, CDK14, CDK1 FGFR4 258/4885KDR 357/4885CDK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.